PTO/SB/08B (8/03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Substitute for form 1449/PTO COMPLETE IF KNOWN **Application Number** 10/501035 Filing Date 01/17/2003 INFORMATION DISCLOSURE **FEI HUANG** First Named Inventor STATEMENT BY APPLICANT(S) Art Unit 1639 (use as many sheets as necessary) **Examiner Name** LIU, SUE XU D0185 US PCT Sheet Attorney Docket Number

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article(when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Check box if English language Translation is attached			
	AA	Sixth Annual Conference – Targeted Therapies in the Treatment of Breast Cancer, July 2003; "Development of Src Kinase Inhibitors for the Treatment of Breast Cancer", Arthur P. DeCillis, Group Director, Oncology Clinical Development, Bristol-Myers Squibb Oncology				
·····						
A						

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant